PR Newswire Clinical TrialsOriginal article
CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints
Phase 2AuxoraPositive
AI Analysis
Summary
CalciMedica announced FDA alignment on the Phase 2b trial design for Auxora in acute pancreatitis, with new-onset severe respiratory failure as the primary endpoint and elevated LDH as a potential enrichment marker.
Clinical Trial Data
Phase
2b
Outcome Details
FDA aligned on Phase 2b trial design with new-onset severe respiratory failure as primary endpoint and multi-organ failure and time to medically indicated discharge as secondary endpoints
Importance:6/10
Sentiment:
0.70
FDA alignmentPhase 2bacute pancreatitistrial designendpointsbiomarker
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on July 29, 2026 11:00 AM